Craig-Hallum Maintains Buy Rating for Delcath Systems (DCTH.US), Adjusts Target Price to $21.00

Summary

Craig-Hallum maintains a buy rating for Delcath Systems, raising the target price from $18.00 to $21.00. Delcath Systems Inc is a company specializing in the treatment of primary and metastatic liver cancer. Its product, Melphalan Hydrochloride for Injection, is used with the Delcath Hepatic Delivery System to deliver high-dose chemotherapy to the liver while controlling systemic exposure and side effects.Stock Star

Impact Analysis

This event is at the company level as it pertains specifically to Delcath Systems. The rating reaffirmation and increased target price suggest positive expectations for the company’s performance, likely driven by potential advancements or market opportunities for its liver cancer treatment products. First-order effects include potential stock price appreciation due to positive investor sentiment. Second-order effects could involve increased investor interest in similar biotechnology firms, particularly those involved in cancer treatment. Investment opportunities may arise from buying Delcath Systems shares, given the optimistic outlook.Stock Star